Direct-to-Consumer Testosterone Not Offered in Accordance With Guidelines
Most direct-to-consumer platforms offer testosterone therapy despite consumer reporting normal testosterone levels, free testosterone
Most direct-to-consumer platforms offer testosterone therapy despite consumer reporting normal testosterone levels, free testosterone
No evidence of increase seen for short- to medium-term cardiovascular risk, but data lacking regarding long-term safety
The approval was based on data from a phase 3 study that evaluated the efficacy and safety of Tlando in 95 adult hypogonadal male patients.
Testosterone therapy in the absence of polycythemia was not associated with an increased risk for major adverse cardiovascular events or venous thromboembolism.
Risk for myocardial infarction or stroke lower with testosterone therapy among men with hypogonadism and other cardiovascular risk factors
Testosterone undecanoate therapy reduces NAFLD grade in obese men with functional hypogonadism and type 2 diabetes
Benefits include significant improvement in body composition measurements over 6 months.
Study reveals an approximately 2-fold increased odds of venous thromboembolism associated with testosterone therapy in men with or without hypogonadism
Testosterone only recommended for postmenopausal women with hypoactive sexual desire dysfunction
Beneficial effects for postmenopausal women, with preference for nonoral testosterone administration